文献速递性腺与生殖内分泌骨质疏松与钙磷/甲状旁腺

跨性别者维生素D结合蛋白及总、生物可利用、游离25羟维生素D的变化

Changes of Vitamin D-Binding Protein, and Total, Bioavailable, and Free 25-Hydroxyvitamin D in Transgender People.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

结果显示维生素D结合蛋白在跨性别女性中有升高趋势、在跨性别男性中无显著变化,总、游离及生物可利用25羟维生素D均无显著改变;总25羟维生素D与生物可利用及游离25羟维生素D相关性良好。

要点

  • 激素治疗3个月未显著改变跨性别者总、游离及生物可利用25羟维生素D浓度。
  • 维生素D结合蛋白在跨性别女性中呈升高趋势(P=0.06),跨性别男性中无显著变化。
  • 总25羟维生素D与生物可利用(R2=0.75)及游离(R2=0.76)25羟维生素D相关性良好,激素治疗不干扰维生素D状态评估。

核心结论

  • 激素治疗未影响跨性别女性及跨性别男性的游离、总及生物可利用25羟维生素D浓度。
  • 总25羟维生素D能较好反映生物可利用及游离25羟维生素D,激素治疗不干扰维生素D状态评估。

研究设计与样本

  • 跨性别女性接受雌二醇和醋酸环丙孕酮,跨性别男性接受睾酮治疗;基线及激素治疗3个月后测量维生素D结合蛋白、总25羟维生素D、游离25羟维生素D及白蛋白,并计算去季节化总25羟维生素D和生物可利用25羟维生素D。

主要发现

  • 维生素D结合蛋白在跨性别女性中变化为+5%(95%CI,-0%至10%;P=0.06),在跨性别男性中为-3%(95%CI:-9%至3%;P=0.34)。
  • 总25羟维生素D、游离及生物可利用25羟维生素D浓度均无显著变化。
  • 总25羟维生素D与生物可利用25羟维生素D(R2=0.75)及游离25羟维生素D(R2=0.76)相关性良好。

临床怎么用

  • 跨性别者接受激素治疗期间,可用总25羟维生素D评估维生素D状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Total 25-hydroxyvitamin D [25(OH)D] is mainly bound to vitamin d-binding protein (DBP). Bioavailable 25(OH)D consists of albumin-bound and free 25(OH)D and is available for metabolic processes. As sex steroids influence DBP, hormonal treatment (HT) in transgender people might affect DBP and consequently the available 25(OH)D. Total 25(OH)D might therefore not well represent bioavailable and free 25(OH)D. OBJECTIVE: To investigate the effects of HT on DBP, and total, bioavailable, and free 25(OH)D, and to assess whether total 25(OH)D well represents bioavailable and free 25(OH)D. DESIGN: A prospective study. SETTING: A university hospital. PARTICIPANTS: Twenty-nine transwomen and 30 transmen. INTERVENTION: Estradiol and cyproterone acetate in transwomen, and testosterone in transmen. MAIN OUTCOME MEASURES: DBP, total 25(OH)D, free 25(OH)D, and albumin were measured at baseline and after 3 months of HT, and deseasonalized total 25(OH)D and bioavailable 25(OH)D were calculated. RESULTS: DBP changed with +5% (95% CI, -0% to 10%; P = 0.06) in transwomen and with -3% (95% CI: -9% to 3%; P = 0.34) in transmen. No significant changes were found in total 25(OH)D, free, and bioavailable 25(OH)D concentrations. Total 25(OH)D was well correlated with bioavailable (R2, 0.75) and free (R2, 0.76) 25(OH)D. CONCLUSIONS: DBP tended to increase in transwomen, but did not change in transmen. HT did not influence free 25(OH)D, total 25(OH)D, and bioavailable 25(OH)D concentrations in transwomen and transmen. As total 25(OH)D represents bioavailable and free 25(OH)D well, HT in transgender people does not interfere with the assessment of vitamin D status.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen H, Wiepjes CM, van Schoor NM, et al. Changes of Vitamin D-Binding Protein, and Total, Bioavailable, and Free 25-Hydroxyvitamin D in Transgender People. J Clin Endocrinol Metab. 2019. PMID: 30785996. doi:10.1210/jc.2018-02602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。